Interleukin-23 Inhibitors
For adult patients with moderate to severe plaque psoriasis scheduled for systemic therapy, FDA-approved agents that act via interleukin-23 (IL-23) inhibition are guselkumab, tildrakizumab, and risankizumab. Response to treatment should be evaluated after a 12-week treatment period in psoriasis pati...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
Galenos Publishing House,
2022-04-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_a1161fecd6c04c29b3ab9d2c46f9db0d | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Esra Adışen |e author |
| 245 | 0 | 0 | |a Interleukin-23 Inhibitors |
| 260 | |b Galenos Publishing House, |c 2022-04-01T00:00:00Z. | ||
| 500 | |a 10.4274/turkderm.galenos.2022.06337 | ||
| 500 | |a 2651-5164 | ||
| 520 | |a For adult patients with moderate to severe plaque psoriasis scheduled for systemic therapy, FDA-approved agents that act via interleukin-23 (IL-23) inhibition are guselkumab, tildrakizumab, and risankizumab. Response to treatment should be evaluated after a 12-week treatment period in psoriasis patients being treated with IL-23 inhibitors. In patients with partial response, dose increase may be planned, or topical corticosteroids, vitamin D analogs, methotrexate, or phototherapy (UVB) may be added to the treatment. | ||
| 546 | |a EN | ||
| 546 | |a TR | ||
| 690 | |a il-23 inhibitor | ||
| 690 | |a guselkumab | ||
| 690 | |a tildrakizumab | ||
| 690 | |a risankizumab | ||
| 690 | |a Dermatology | ||
| 690 | |a RL1-803 | ||
| 690 | |a Diseases of the genitourinary system. Urology | ||
| 690 | |a RC870-923 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Turkderm Turkish Archives of Dermatology and Venereology, Vol 56, Iss Suppl 1, Pp 61-66 (2022) | |
| 787 | 0 | |n https://journal.turkderm.org.tr/jvi.aspx?pdir=turkderm&plng=eng&un=TURKDERM-06337&look4= | |
| 787 | 0 | |n https://doaj.org/toc/2651-5164 | |
| 856 | 4 | 1 | |u https://doaj.org/article/a1161fecd6c04c29b3ab9d2c46f9db0d |z Connect to this object online. |